Technology | October 17, 2007

EZ-EM to Spotlight Injectors, VoLumen Oral Contrast

EmpowerCTA injector offers both E-Z-EM’s patented extravasation detection accessory (EDA) and a saline chase. Modular CT injector features air embolism protection, on-the-fly flow rate manipulation, easy syringe loading and arming at the injector. IRiS software tracks: patient ID, creatinine values, GFR, consumable utilization, total contrast filled/injected/wasted, type of contrast, EDA activation status and number of EDA-identified extravasations.

Also featured, the E-Z-EM EmpowerMR injector reportedly provides virtually no injector RF in the scanner room, consistent flow rate delivery, pressure performance on demand, improved productivity and compatibility up to 7T environments.
EmpowerMR employs a hydraulic control system instead of the shielded electrical control components used by most other MR injector systems. EmpowerMR has no shielded iron motors, piezoelectric motors and electrically active motor control circuitry adjacent to the scanner, which significantly minimizes the prospect of electrical interference with the scanner's magnetic field. EmpowerMR is also not battery operated, and links to its electrical supply by a single pass-through cable that does not require special shielding.

E-Z-EM’s VoLumen is a low Hounsfield value oral contrast for MDCT and PET/CT studies designed to overcome the limitations of water and other higher-density positive oral contrasts. It reportedly allows for the simultaneous investigation of all organs, vasculature and surrounding structures of the abdominal/pelvic region and is used in CT Enterography (CTE) for the diagnosis/evaluation of Crohn's disease and other inflammatory bowel disease. It also reportedly minimizes X-ray attenuation, reducing isotope uptake artifacts in PET/CT. VoLumen does not convert to glucose, so it does not interfere with the injection of the glucose-based radioactive contrasts.

Related Content

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabri
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
FDA says gadolinium retention in the brain is not a safety issue
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for...
Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017
A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has engineered a...
Scientists Develop Novel Chemical Dye to Improve MRI Liver Cancer Imaging
News | Magnetic Resonance Imaging (MRI) | May 03, 2017
May 3, 2017 — Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based ...
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Overlay Init